Therapeutics Company Reports Positive Results For Cancer Therapy
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort.
Indaptus Therapeutics Inc. (NASDAQ: INDP), a pioneering biopharmaceutical company, has recently announced encouraging results from the second cohort of its Phase 1 clinical trial. This announcement marks a significant milestone in the company's relentless efforts to develop groundbreaking therapies for cancer patients. $Indaptus Therapeutics(INDP.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
